肺癌患者血清可溶性白细胞介素-2受体水平测定及其临床意义

Clinical significance of serum soluble interleukin 2 receptor levels in patients with lung cancer

采用双抗体夹心酶联免疫吸附试验检测３２例手术前后和２６例化疗前后肺癌患者的血清可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）水平并与２９例健康人进行比较。结果显示：肺癌患者血清ｓＩＬ－２Ｒ水平明显高于正常对照组（Ｐ＜０．０１）。术后患者血清ｓＩＬ－２Ｒ水平明显下降（Ｐ＜０．０１）；术前血清ｓＩＬ－２Ｒ水平与肿瘤组织分化密切相关，分化越低，水平越高（Ｐ＜０．０５），但与肿瘤病理类型和分期无明显的关系（Ｐ＞０．０５）。化疗前后ｓＩＬ－２Ｒ水平变化不明显（Ｐ＞０．０５）。，而且ｓＩＬ－２Ｒ水平下降与化疗疗效也无明显的关系（Ｐ＞０．０５）。结果表明肺癌患者血清ｓＩＬ－２Ｒ水平与肿瘤负荷和肿瘤分化密切相关，血清ｓＩＬ－２Ｒ水平动态监测可以作为判断手术效果和肿瘤预后的重要指标。

The aim of this study was designed to determine the serum sIL 2R level as an index of tumor burden, and its predictive value in response to chemotherapy and prognosis. The serum levels of sIL 2R were measured by an Enzyme linked Immunosorbent Assay in 58 lung cancer patients (32 cases with operation and 26 with chemotherapy) and 29 healthy adults served as controls. The results showed that the serum sIL 2R levels in lung cancer patients were significantly higher than those of healthy controls ( P <0.01). The serum levels of sIL 2R were reduced obviously after operation ( P <0.01), and were closely related to the histological differentiation of tumor ( P <0.05), but no correlations were noted among the sIL 2R level, pathological type, and TNM stage( P >0.05). The serum levels after chemothrapy were not different from those of prechemotherapy ( P >0.05). Meanwhile, the reduced levels of IL 2R were not related to the immediate response to chemotherapy ( P >0.05). These results seem to suggest that monitoring serum IL 2R levels has clinical and prognositic significance in patients with lung cancer.